Clinical Trial Search

Primary: Maximum Tolerated Dose of Tandutinib Defined by Dose Limiting Toxicities (Phase 1) — 600 mg BID

Primary: Everolimus Maximum Tolerated Dose (MTD) [Phase I] — 10 mg daily for 4 weeks of a 4 week cycle

Primary: Percentage of Participants Achieving 75 Percent Reduction From Baseline Psoriasis Area and Severity Index (PASI) Score (PASI75 Response) at Week 12 — 8.7; 9.5; 0; 5.3…

Primary: Percentage of Participants With Steady State Drug Concentration Ctrough (Cycle 6 Pre-dose) >20 µg/mL at Cycle 5. — 92.1; 93.3 Percentage of participants

Primary: PASI 75 Response Rate at Week 16 - GP2017 Adalimumab vs Humira ® Adalimumab — 66.8; 65.0 percent of participants

Primary: Time-weighted Mean Change From Baseline in Western Ontario McMaster (WOMAC) Pain Through Week 12 of Treatment — -28.25; -25.89; -25.74 millimeter(mm) — p=0.1626

Primary: Abstinence (Week 1 - 12) — 27; 14; 38; 13 Participants

Primary: Number of Participants With Induced Peanut Desensitization at 12 Months — 9; 7 Participants

Primary: NAA/Cr Ratio — 1.47; 1.38; 1.62; 1.41 Ratio

Primary: Percentages of Subjects With RVNA Titer >= 0.5 and Vaccine Group Differences ("4-sites, 1-week" to That of "2-sites, TRC" ID PEP Regimen of the PCEC Rabies Vaccine With…

Primary: Change From Baseline in Hemoglobin A1C (HbA1C) at Week 26 - Full Analysis Set (FAS Population Excluding Rescue Approach — -1.60; -1.68; -0.44 Percentage — p=< 0.001

Primary: Complete Response — 3 participants

Primary: Percent Change From Baseline in Body Weight at 6 Months — 10.2; 12.7 percentage change

Primary: Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007) — 0 objective response

Primary: Contrast Sensitivity as Assessed by Mars Contrast Sensitivity Chart — 1.866; 1.861; 1.856; 1.818 log contrast sensitivity score